Compare stocks

CANF vs LTRN

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares and Lantern Pharma Inc. Common Stock

Compare the businesses

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Open CANF dashboard ↗

Lantern Pharma Inc. Common Stock

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Open LTRN dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗